05322nam 22006494a 450 991014469880332120170919210923.01-282-35017-X97866123501770-470-98579-80-470-98578-X(CKB)1000000000687511(EBL)470159(OCoLC)609848740(SSID)ssj0000312772(PQKBManifestationID)11223169(PQKBTitleCode)TC0000312772(PQKBWorkID)10332302(PQKB)10941282(MiAaPQ)EBC470159(PPN)199221944(EXLCZ)99100000000068751120071207d2008 uy 0engur|n|---|||||txtccrViral therapy of cancer[electronic resource] /editors, Kevin J. Harrington, Richard G. Vile, Hardev S. PandhaChichester, England ;Hoboken, NJ John Wiley & Sonsc20081 online resource (426 p.)Description based upon print version of record.0-470-01922-0 Includes bibliographical references and index.Viral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV7.7 Combination of oncolytic HSV with immunomodulatory gene expressionIn the last decade there has been an explosion of interest in viral therapies for cancer. Viral agents have been developed that are harmless to normal tissues but selectively able to kill cancer cells. These agents have been endowed with additional selectivity and potency through genetic manipulation. Increasingly these viruses are undergoing evaluation in clinical trials, both as single agents and in combination with standard chemotherapy and radiotherapy. This book provides a comprehensive yet succinct overview of the current status of viral therapy of cancer. Chapters coherently present VirusesTherapeutic useCancerTreatmentVirusesTherapeutic use.CancerTreatment.616.99/406616.99406Harrington Kevin J.1958-38288Pandha Hardev949550Vile Richard G78071MiAaPQMiAaPQMiAaPQBOOK9910144698803321Viral therapy of cancer2146250UNINA